title: [Retroperitoneal lymph node dissection for patients with advanced testicular tumor].
abstract: We examined the indication for retroperitoneal lymph node dissection (RPLND) for 30 patients with advanced testicular tumor and made the following conclusion. The sequence of RPLND and primary chemotherapy made no difference in the therapeutic effect for patients with stage II A non-seminomatous germ cell tumor (NSGCT). However, we thought it better to administer primary chemotherapy prior to RPLND to prevent dissemination of tumor cells. Viable tumor cells often remained in retroperitoneal residual tumors even after chemotherapy in the patients with NSGCT advanced beyond stage II B. Therefore, RPLND seemed to be necessary if residual retroperitoneal tumors were found after the chemotherapy. In patients with seminoma, RPLND did not seem to be necessary if the residual tumor was less than 3 cm in diameter or the reduction rate of the retroperitoneal tumor was more than 80% after the initial therapy (chemotherapy or irradiation therapy.
authors.affiliation: Department of Urology, Osaka Medical College.
authors.forename: N
authors.initials: N
authors.lastname: Takasaki
authors.forename: H
authors.initials: H
authors.lastname: Ueda
authors.forename: K
authors.initials: K
authors.lastname: Isurugi
mesh_terms: D002945:Cisplatin / Q000008:administration & dosage; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D018365:Neoplasm, Residual; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000556:secondary / Q000601:surgery*; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000601:surgery*; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*
chemical_list: D002945:Cisplatin